Resource Center

Mar 4, 2021
  |  Video

Regulatory Perspectives for Reliable Model Informed Drug Development (MIDD)

Sarem Sarem, Biostat Unit, Office of Science Therapeutic Products Directorate, Health Canada, presents his thoughts on MIDD, Pharmacometrics, and Modeling & Simulation approaches in Phase III of drug development.

Topics covered:

  • Common model-informed drug development applications for regulatory submissions
  • Understanding the benefits and risks of a drug for the intended use and patient population
  • Good Data + Good Model + Good Analysis
  • and more!

Download Slides

Presented at SLP MIDD+ Virtual Conference March 3-4, 2021

Disclaimer: This presentation reflects the views and thoughts of the author and should not be considered to represent Health Canada’s views or policies

 

Contact Us About This Video